1. P-191Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND). (2nd July 2019) Authors: Aparicio, J; Virgili, A; Capdevila, J; Muñoz Boza, F; Álvarez, R; Bosch, C; Cámara, J; Fernandez-Martos, C; Fernandez-Plana, J; Gallego, J; Gallego, R; Hernández-Yagüe, X; Macías Declara, I; Rodríguez-Salas, N; Vera, R; Taberner, M; Maurel, J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 478PIn the pathway to response: Is aflibercept an optimal treatment for RASwt mCRC patients after progression to 1st line containing anti-EGFR?. (23rd October 2018) Authors: Mata Velasco, E; González-Flores, E; Juez Martel, I; Alonso, V; Iranzo Gomez, P; Martinez Lago, N; Lopez, C; Cabrera Romero, J M; Safont Aguilera, M J; Ruiz Casado, A; Salgado Fernandez, M; González Astorga, B; Escudero, P; Rivera Herrero, F; Pericay Pijaume, C; Vera, R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P-276Raltitrexed as salvage therapy for metastatic colorectal cancer: A multicenter retrospective study. (20th June 2018) Authors: Ghanem, I; Viudez, A; García-Torralba, E; Torres-Tenor, J; Carmona, A; Vera, R; Rodriguez-Salas, N; de la Peña, F Ayala; Higuera, O; Feliu, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 54PDPre-treatment CD4 senescent T cells accurately predicts lack of response to PD-L1/PD-1 immune checkpoint blockade in non-small cell lung cancer and correlates with risk of hyperprogression. (23rd October 2018) Authors: Zuazo, M; Arasanz, H; Gato-Cañas, M; Fernández-Hinojal, G; Hernández-Marín, B; Martínez-Aguillo, M; Ibáñez-Vea, M; Lecumberri Biurrun, M J; Fernández de Lascoiti, Á; Vera, R; Kochan, G; Escors, D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 26PIsoform-specific AKT inhibition differentially affects cell functions in pancreatic adenocarcinoma. (23rd October 2018) Authors: Arasanz, H; Gato-Cañas, M; Zuazo, M; Ibáñez-Vea, M; Fernández-Hinojal, G; Fernandez-Irigoyen, J; Santamaria, E; Kochan, G; Vera, R; Escors, D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial. Issue 6 (May 2017) Authors: Pineda, Estela; Salud, A; Vila-Navarro, E; Safont, MJ; Llorente, Beatriz; Aparicio, J; Vera, R; Escudero, P; Casado, E; Bosch, C; Bohn, U; Pérez-Carrión, R; Carmona, A; Ayuso, JR; Ripollés, T; Bouzas, R; Gironella, M; García-Albéniz, X; Feliu, J; Maurel, J Journal: Tumor biology Issue: Volume 39:Issue 6(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗